Dosing & Uses
Dosage Forms & Strengths
capsule
- Lovaza: 1g; 900mg of ethyl esters; includes eicosapentaenoic acid (EPA ~465mg) and docosahexaenoic acid (DHA ~375mg)
- Omtryg: 1.2g; 900mg of ethyl esters; includes eicosapentaenoic acid (EPA ~465mg) and docosahexaenoic acid (DHA ~375mg)
- Vascazen: 1g; 900mg of ethyl esters; includes eicosapentaenoic acid (EPA ~680mg) and docosahexaenoic acid (DHA ~110mg)
Hypertriglyceridemia (Lovaza, Omtryg)
Adjunct to diet in patients with triglycerides ≥500 mg/dL
Lovaza: 4 g (4 capsules) PO qDay or 2 g (2 capsules) PO BID
Omtryg: 4.8 g (4 capsules) PO qDay or 2.4 g (2 capsules) PO BID
Omega-3 Fatty Acid Deficiency (Vascazen)
Prescription medical food specifically formulated to correct an omega-3 deficiency in cardiovascular patients
Vascazen: 4 g/day PO qDay or divided BID
<18 years: Safety and efficacy not established
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (25)
- alteplase
omega 3 fatty acids, alteplase. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- anagrelide
omega 3 fatty acids, anagrelide. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- antithrombin alfa
omega 3 fatty acids, antithrombin alfa. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- antithrombin III
omega 3 fatty acids, antithrombin III. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- argatroban
omega 3 fatty acids, argatroban. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- aspirin
omega 3 fatty acids, aspirin. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- aspirin/citric acid/sodium bicarbonate
omega 3 fatty acids, aspirin/citric acid/sodium bicarbonate. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- betrixaban
omega 3 fatty acids, betrixaban. Either increases levels of the other by anticoagulation. Use Caution/Monitor.
- bivalirudin
omega 3 fatty acids, bivalirudin. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- clopidogrel
omega 3 fatty acids, clopidogrel. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- dabigatran
omega 3 fatty acids, dabigatran. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- dalteparin
omega 3 fatty acids, dalteparin. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- desirudin
omega 3 fatty acids, desirudin. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- dipyridamole
omega 3 fatty acids, dipyridamole. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- enoxaparin
omega 3 fatty acids, enoxaparin. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- fondaparinux
omega 3 fatty acids, fondaparinux. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- heparin
omega 3 fatty acids, heparin. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- prasugrel
omega 3 fatty acids, prasugrel. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- reteplase
omega 3 fatty acids, reteplase. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- tenecteplase
omega 3 fatty acids, tenecteplase. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- ticlopidine
omega 3 fatty acids, ticlopidine. Other (see comment). Use Caution/Monitor. Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .
- vorapaxar
omega 3 fatty acids, vorapaxar. Either increases effects of the other by anticoagulation. Use Caution/Monitor. Coadministration of anticoagulants, antiplatelets, or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding.
- vortioxetine
omega 3 fatty acids, vortioxetine. Either increases effects of the other by anticoagulation. Use Caution/Monitor.
- warfarin
omega 3 fatty acids increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor.
- zanubrutinib
omega 3 fatty acids, zanubrutinib. Either increases effects of the other by anticoagulation. Modify Therapy/Monitor Closely. Zanubrutinib-induced cytopenias increases risk of hemorrhage. Coadministration of zanubritinib with antiplatelets or anticoagulants may further increase this risk.
Minor (0)
Adverse Effects
1-10%
Eructation (4.9%)
Infection (4.4%)
Flu-like syndrome (3.5%)
Dyspepsia (3.1%)
Taste perversion (2.7%)
Back pain (2.2%)
Pain (1.8%)
Rash (1.8%)
Angina pectoris (1.3%)
Postmarketing Reports
Anaphylactic reaction
Hemorrhagic diathesis
Urticaria
Warnings
Contraindications
Hypersensitivity
Cautions
Discontinue medications that exacerbate hypertriglyceridemia
Use caution in patients allergic to fish
May increase liver ALT without increasing AST (monitor)
May increase LDL levels (monitor)
May prolong bleeding time (use caution)
Recurrent AF or flutter observed when initial high dose of Lovaza administered (ie, 8 g/day x1 week, then 4 g/day thereafter)
Pregnancy & Lactation
Pregnancy
Available data from published case reports and pharmacovigilance database on use in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes
Animal data
- In animal studies, omega-3-acid ethyl esters given orally to female rats prior to mating through lactation did not have adverse effects on reproduction or development when given at doses 5 times maximum recommended human dose (MRHD) of 4 grams/day, based on a body surface area comparison; omega-3-acid ethyl esters given orally to rats and rabbits during organogenesis was not teratogenic at clinically relevant exposures, based on body surface area comparison
Lactation
Published studies have detected omega-3 fatty acids, including EPA and DHA, in human milk
Lactating women receiving oral omega-3 fatty acids for supplementation have resulted in higher levels of omega-3 fatty acids in human milk
There are no data available on effects of omega- 3 fatty acid ethyl esters on breastfed infant or on milk production
Developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Possibly inhibits acyl CoA: 1,2-diacylglycerol acyltransferase, increases peroxisomal beta-oxidation in liver; may decrease hepatic triglyceride synthesis; plasma lipoprotein lipase activity may increase
Absorption
Rapid
Administration
Instructions
Swallow capsules whole; do not chew, crush, break, or dissolve
Lovaza, Vascazen: May take with or without food
Omtryg: Take with food
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Fish Oil oral - | 1,600-500-800 mg/5 mL liquid |  | |
| Fish Oil oral - | 300-1,000 mg capsule |  | |
| Fish Oil oral - | 60-90-500 mg capsule |  | |
| Fish Oil oral - | 120-180 mg capsule |  | |
| Fish Oil oral - | 340-1,000 mg capsule |  | |
| Fish Oil oral - | 300-1,000 mg capsule |  | |
| Fish Oil oral - | 300-1,000 mg capsule |  | |
| Fish Oil oral - | 360-1,200 mg capsule |  | |
| omega-3 fatty acids oral - | 1,000 mg capsule |  |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
